- Home
- URGN vs FLNC Comparison
URGN vs FLNC Comparison
Compare URGN & FLNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | URGN | FLNC |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 974.7M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | URGN | FLNC |
|---|---|---|
| Price | $21.96 | $22.15 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 20 |
| Target Price | ★ $28.50 | $13.74 |
| AVG Volume (30 Days) | 928.6K | ★ 6.8M |
| Earning Date | 11-06-2025 | 11-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $96,516,000.00 | ★ $2,262,830,000.00 |
| Revenue This Year | $27.96 | $48.80 |
| Revenue Next Year | $123.02 | $19.81 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 8.00 | N/A |
| 52 Week Low | $3.42 | $3.46 |
| 52 Week High | $30.00 | $25.81 |
Technical Indicators
Market Signals| Indicator | URGN | FLNC |
|---|---|---|
| Relative Strength Index (RSI) | 42.19 | 56.33 |
| Support Level | $21.74 | $18.52 |
| Resistance Level | $30.00 | $24.79 |
| Average True Range (ATR) | 1.56 | 2.27 |
| MACD | -0.72 | 0.42 |
| Stochastic Oscillator | 3.15 | 67.34 |
Price Performance
Historical ComparisonAbout URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About FLNC Fluence Energy Inc.
Fluence Energy Inc is enabling the global clean energy transition with market-leading energy storage products and services, and digital applications for renewables and storage. Geographically, it derives a majority of its revenue from the Americas.